RLMD
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. insider trading
Relmada Therapeutics, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent RLMD insider transactions
The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.
SEC Form 4 data, Q3 2024 to Q2 2026
RLMD insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 5 insiders traded RLMD on the open market: 25 purchases worth $3.6M and 0 sales. In the last four quarters alone: 9 purchases ($2.5M) and 0 sales, by 4 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | +$2.4M6 buys | — | |
| Q3 2025 | +$178.1K3 buys | — | |
| Q2 2025 | +$461.6K8 buys | — | |
| Q1 2025 | — | — | |
| Q4 2024 | — | — | |
| Q3 2024 | +$642.8K8 buys | — |
- Largest purchase
- +$1.1M of RLMD by Shenouda Maged (Chief Financial Officer) on Nov 05, 2025.
Open-market transactions through Jun 30, 2026most recent first
Traversa Sergio
Chief Executive Officer · Director
+$113.3K
Dec 15, 2025
27,500 sh · $4.12
Shenouda Maged
Chief Financial Officer
+$48.1K
Dec 15, 2025
11,665 sh · $4.12
Shenouda Maged
Chief Financial Officer
+$1.1M
Nov 05, 2025
500,000 sh · $2.20
Traversa Sergio
Chief Executive Officer · Director
+$599.5K
Nov 05, 2025
272,500 sh · $2.20
Ence Chuck
CAO and COO
+$299.2K
Nov 05, 2025
136,000 sh · $2.20
Kelly Paul Edward
Chief Operating Officer · Director
+$198K
Nov 05, 2025
90,000 sh · $2.20
Traversa Sergio
Chief Executive Officer · Director
+$41.4K
Aug 28, 2025
55,976 sh · $0.74
Traversa Sergio
Chief Executive Officer · Director
+$86.7K
Aug 27, 2025
129,455 sh · $0.67
Traversa Sergio
Chief Executive Officer · Director
+$49.9K
Aug 26, 2025
80,545 sh · $0.62
Traversa Sergio
Chief Executive Officer · Director
+$82.7K
May 20, 2025
147,686 sh · $0.56
Shenouda Maged
Chief Financial Officer
+$31.2K
May 20, 2025
60,000 sh · $0.52
Shenouda Maged
Chief Financial Officer
+$44.1K
May 19, 2025
90,000 sh · $0.49
Traversa Sergio
Chief Executive Officer · Director
+$15K
May 19, 2025
30,000 sh · $0.50
Ence Chuck
CA and CO
+$103K
May 16, 2025
228,960 sh · $0.45
Kelly Paul Edward
Chief Operating Officer · Director
+$86K
May 16, 2025
200,000 sh · $0.43
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 15, 2025 | Traversa SergioChief Executive Officer · Director | 27,500 | $4.12 | +$113.3K |
| Dec 15, 2025 | Shenouda MagedChief Financial Officer | 11,665 | $4.12 | +$48.1K |
| Nov 05, 2025 | Shenouda MagedChief Financial Officer | 500,000 | $2.20 | +$1.1M |
| Nov 05, 2025 | Traversa SergioChief Executive Officer · Director | 272,500 | $2.20 | +$599.5K |
| Nov 05, 2025 | Ence ChuckCAO and COO | 136,000 | $2.20 | +$299.2K |
| Nov 05, 2025 | Kelly Paul EdwardChief Operating Officer · Director | 90,000 | $2.20 | +$198K |
| Aug 28, 2025 | Traversa SergioChief Executive Officer · Director | 55,976 | $0.74 | +$41.4K |
| Aug 27, 2025 | Traversa SergioChief Executive Officer · Director | 129,455 | $0.67 | +$86.7K |
| Aug 26, 2025 | Traversa SergioChief Executive Officer · Director | 80,545 | $0.62 | +$49.9K |
| May 20, 2025 | Traversa SergioChief Executive Officer · Director | 147,686 | $0.56 | +$82.7K |
| May 20, 2025 | Shenouda MagedChief Financial Officer | 60,000 | $0.52 | +$31.2K |
| May 19, 2025 | Shenouda MagedChief Financial Officer | 90,000 | $0.49 | +$44.1K |
| May 19, 2025 | Traversa SergioChief Executive Officer · Director | 30,000 | $0.50 | +$15K |
| May 16, 2025 | Ence ChuckCA and CO | 228,960 | $0.45 | +$103K |
| May 16, 2025 | Kelly Paul EdwardChief Operating Officer · Director | 200,000 | $0.43 | +$86K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check RLMD — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Relmada Therapeutics, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- How much RLMD stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 5 Relmada Therapeutics, Inc. insiders made 25 open-market purchases worth $3.6M and no sales. In the four quarters to Jun 30, 2026: 9 purchases ($2.5M) and no sales. The largest purchase was Shenouda Maged buying $1.1M on Nov 05, 2025.
- Where does RLMD insider trading data come from?
- From the Form 4 filings Relmada Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.